Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : xRNA-based Therapy
Therapeutic Area : Nephrology
Study Phase : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $150.0 million
Deal Type : Series A Financing
Versant Ventures and Novartis Launch Borealis Biosciences with $150 Million in Funding
Details : The company will use the proceeds to focus on discovering next-generation next-generation xRNA-based medicines for kidney diseases using xRNA technology platform innovation.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 22, 2024
Lead Product(s) : xRNA-based Therapy
Therapeutic Area : Nephrology
Highest Development Status : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $150.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?